Medifast (MED) Stock Price, News & Analysis

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12 month target prices for Medifast's stock. Their MED share price targets range from $40.00 to $82.00. On average, they expect the company's stock price to reach $61.00 in the next year. This suggests a possible upside of 87.7% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $67.22 at the beginning of 2024. Since then, MED stock has decreased by 51.7% and is now trading at $32.50.
View the best growth stocks for 2024 here.

Medifast saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,660,000 shares, an increase of 29.8% from the March 15th total of 2,050,000 shares. Based on an average daily trading volume, of 384,900 shares, the days-to-cover ratio is currently 6.9 days. Approximately 25.1% of the shares of the stock are short sold.
View Medifast's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, April 29th 2024.
View our MED earnings forecast.

Medifast will be holding an earnings conference call on Monday, April 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 844-512-2921 with passcode "13745406".

Medifast, Inc. (NYSE:MED) issued its earnings results on Tuesday, February, 20th. The specialty retailer reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.10. The specialty retailer had revenue of $191.02 million for the quarter, compared to analyst estimates of $184.17 million. Medifast had a net margin of 9.27% and a trailing twelve-month return on equity of 56.06%. The business's revenue for the quarter was down 43.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.70 earnings per share.

Medifast announced a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 20.31%. The ex-dividend date of this dividend is Monday, September 18th.
Read our dividend analysis for MED.

Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 0.00%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 72.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, MED will have a dividend payout ratio of 132.00% in the coming year. This indicates that the company may not be able to sustain their current dividend.
Read our dividend analysis for MED.

ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Invesco S&P SmallCap Consumer Staples ETF (PSCC), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS) and Global X Health & Wellness ETF (BFIT).

Medifast updated its first quarter 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of 0.250-0.950 for the period, compared to the consensus earnings per share estimate of 1.490. The company issued revenue guidance of $155.0 million-$175.0 million, compared to the consensus revenue estimate of $205.8 million.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.39%), Chickasaw Capital Management LLC (0.17%), DGS Capital Management LLC (0.10%), Aviance Capital Partners LLC (0.08%) and Rowlandmiller & PARTNERS.ADV (0.03%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.